Loading...
Cet enregistrement a été supprimé. Comme ce document est lié à un enregistrement publié, il est disponible ici à titre de référence uniquement.
Cliquez ici pour consulter l'enregistrement suppriméCe document a été mis à jour. Il ne s’agit pas de la dernière version publiée. Cliquez ici pour voir la dernière version du fichier.
Organisme vivant modifié
(LMO)
L’image ci-dessous identifie l’OVM par son identificateur unique, son nom commercial et un lien vers cette page du Centre d’échange Cliquer dessus pour télécharger une plus grande image sur votre ordinateur Pour du soutien sur comment utiliser, aller dans la page de liens rapides OVM.
VECTORMUNE® FP-LT + AE Vaccine
EN
FP/LT
Non
-
Personne :Dr Alexis Henry Gaetan GouxPresident of CIBio,Rua Manuel Joaquim Filho, 303 Pulínia - SPPaulínia, São Paulo
13140-000, BrésilTéléphone : 551938337700,Télécopieur : 55193833-7722,E-mail : alexisgoux@ceva.com,Site Web : http://www.ceva.com.br/,Organisations reliéesCeva Saúde Animal Ltda (CEVA)Secteur privé (affaires et industrie)Rua Manuel Joaquim Filho, 303 Pulínia - SPPaulínia, São Paulo
13140-000, BrésilTéléphone : 551938337700,Télécopieur : 55193833-7722,E-mail : alexisgoux@ceva.com,Site Web : http://www.ceva.com.br/,
VECTORMUNE FP-LT + AE is a genetically engineered, live fowlpox virus vaccine for use in chickens. The fowlpox virus has been genetically modified to express key protective laryngotracheitis (LT) virus antigens. In addition to the fowlpox virus vector, this freeze-dried vaccine contains a conventional live avian encephalomyelitis (AE) virus for use as an aid in the prevention of avian encephalomyelitis.
EN
Le terme « organisme récepteur » désigne un organisme (non modifié ou déjà modifié) ayant fait l'objet d'une modification génétique, tandis que les « organismes parentaux » désignent les organismes impliqués dans un croisement ou une fusion cellulaire pour générer un organisme modifié.
-
BCH-ORGA-SCBD-105171-4 Organisme Fowlpox virus (FOWPV)Virus
FR
-
VECTORMUNE® FP-LT Vaccine| Ceva Saúde Animal Ltda(CEVA) | Production de composés médicaux ou pharmaceutiques (humains ou animaux) (Vaccins)
pUC18
EN
- Autres (Homologous Recombination)
Certains de ces éléments génétiques peuvent être présents sous forme de fragments ou sous forme tronquée. Veuillez consulter les notes ci-dessous, s’il y a lieu.
-
BCH-GENE-SCBD-105174-2 Glycoprotein B gene | Gallid alphaherpesvirus 1 (ILTV)Séquence codante de protéines | Production de composés médicaux ou pharmaceutiques (humains ou animaux) (Vaccins)
-
BCH-GENE-SCBD-105173-2 UL32 gene | Gallid alphaherpesvirus 1 (ILTV)Séquence codante de protéines | Production de composés médicaux ou pharmaceutiques (humains ou animaux) (Vaccins)
Two genes originating from ILTV, namely UL32 and gB, were introduced into a FPV vector. The genes were ligated into a pUC18 transformation vector in addition to a lacZ marker gene from E. coli, using two synthetic promoters and an FPV homologous recombination site.
The vector was constructed by cloning a 3 kb fragment of FPV genomic DNA into the pUC18 vector. An internal fragment of 175bp was removed and replaced by a construct containing the UL32 coding sequenece with a synthetic PS promoter, followed by a lacZ gene directed by the synthetic promoter P17. This was followed by the coding sequence of the gB gene which was also directed by the synthetic promoter PS.
The synthetic promoters PS and P17 emulate the consensus early/late promoter and the early poxvirus promoter, respectively. Genes gB and UL32 code for the ILTV antigens, while the gene lacZ operates as a reporter gene to facilitate recombinant virus selection.
This construct and the the parental FPV strain were co-transformed into chicken embryo fibroblasts and incubated under conditions that favour homologous recombination.
Homologous recombination and integration of the genetic construct was confirmed by Southern blot using probes that hybridized in both sides of the insertion site. DNA sequencing was also conducted. Expression of genes UL32 and gB was confirmed by Western blot.
EN
The vector was constructed by cloning a 3 kb fragment of FPV genomic DNA into the pUC18 vector. An internal fragment of 175bp was removed and replaced by a construct containing the UL32 coding sequenece with a synthetic PS promoter, followed by a lacZ gene directed by the synthetic promoter P17. This was followed by the coding sequence of the gB gene which was also directed by the synthetic promoter PS.
The synthetic promoters PS and P17 emulate the consensus early/late promoter and the early poxvirus promoter, respectively. Genes gB and UL32 code for the ILTV antigens, while the gene lacZ operates as a reporter gene to facilitate recombinant virus selection.
This construct and the the parental FPV strain were co-transformed into chicken embryo fibroblasts and incubated under conditions that favour homologous recombination.
Homologous recombination and integration of the genetic construct was confirmed by Southern blot using probes that hybridized in both sides of the insertion site. DNA sequencing was also conducted. Expression of genes UL32 and gB was confirmed by Western blot.
FR
- Vaccin
FR
FR
- Vectormune® FP-LT+AE - Biomune Company [ English ]
- Vectormune® FP-LT+AE - CTNBio [ English ]
| Type de fichier | Champs | Fichier(s) : | |
|---|---|---|---|
| Décision de pays ou tout autre communication | Identification de l'OVM | 2 | |
| Évaluation des risques générée par un processus de réglementation | Organisme(s) vivant(s) modifié(s) | 2 | |
| Organisme vivant modifié | OVM connexe(s) | 1 | |